transforming growth factor beta 2 inhibitor
Total Trials
1
As Lead Sponsor
0
As Collaborator
NCT05935774
OT-101 in Combination With Atezolizumab for the Treatment of Metastatic or Recurrent Non-Small Cell Lung Cancer
Phase: Phase 2
Role: Collaborator
Start: Dec 1, 2023
Completion: Jul 31, 2028
Loading map...